1. Transforming body composition with semaglutide in adults with obesity and type 2 diabetes mellitus
- Author
-
Beatriz Rodríguez Jiménez, Pablo Rodríguez de Vera Gómez, Samuel Belmonte Lomas, Ángel Manuel Mesa Díaz, Irene Caballero Mateos, Irene Galán, Cristóbal Morales Portillo, and María Asunción Martínez-Brocca
- Subjects
obesity ,type 2 diabetes mellitus ,body composition ,phase angle ,fat mass ,lean body mass ,Diseases of the endocrine glands. Clinical endocrinology ,RC648-665 - Abstract
BackgroundGlucagon-like peptide-1 receptor-agonists (GLP-1ra), such as semaglutide, have emerged as promising treatments, demonstrating sustained weight reduction and metabolic benefits. This study aims to assess the impact of oral and subcutaneous semaglutide on body composition and metabolic parameters in patients with T2DM and obesity.MethodsA 24-week quasi-experimental retrospective study including adults with T2DM and obesity (BMI ≥ 30 kg/m²) who were treated with either daily-oral or weekly-subcutaneous semaglutide. Body composition was measured using bioelectrical impedance analysis, evaluating fat mass, fat-free mass, total body water, skeletal muscle mass, and whole-body phase angle. Analytical parameters included lipid profile and glycaemic control. Statistical analyses were performed using SPSS v.26.ResultsParticipants (n=88) experienced significant weight loss after treatment with semaglutide (9.5% in subcutaneous, 9.4% in oral, P
- Published
- 2024
- Full Text
- View/download PDF